Pulished : October, 2018
ID: 95
Region: Global
Share on

Market Data Forecast report predicts that the ‘Global Bladder Cancer Therapeutics Market’ is predicted to reach USD 677.6 million by 2021 with a CAGR of 4.85%

Pulished: October, 2018
ID: 95
Share on

The Global Bladder Cancer Therapeutics Market report published by Market Data Forecast provides a detailed account of the Market Trends via Customized Research presented as Strategic Analyses, Company Profiles, and Competitive Landscape etc. According to the report, the Global Bladder Cancer Therapeutics Market is projected to reach USD 677.6 million by 2021 from USD 534.7 million in 2016 with a CAGR of 4.85%. The market is segmented based on type and treatment. Based on type, the market is further sub-segmented as Transitional Cell Bladder Cancer, Non Muscle Invasive/Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer, Adenocarcinoma of the Bladder, and Rare Bladder Cancers. Based on treatment, the market is further segmented as Surgery, Chemotherapy, Immunotherapy, Radiation Therapy, and Intravesical Therapy. Further the market is also geographically segmented into North America, Europe, Asia-Pacific, Latin America, and Middle-East & Africa.

Growing number innovative treatments (such as targeted therapies & biological treatments), rising awareness among people about bladder cancer therapies, and increasing healthcare expenditure are driving the growth of global bladder cancer therapeutics market. In addition, growing research in the development of innovative bladder cancer therapies and presence of pipeline therapeutics are further propelling the growth of global bladder cancer therapeutics market. However, high cost of bladder cancer therapies, limited adoption of advanced cancer therapies, stringent regulatory policies, and poorly developed healthcare infrastructure are restraining the growth of global bladder cancer therapeutics market.

North America accounted for the largest market share of 41.0% of global Bladder Cancer Therapeutics market owing to increasing innovations in cancer research, rising number of product launches, presence of major market players, and growing number of collaborations & agreements to promote bladder cancer therapies. Asia-Pacific region is expected to grow at the highest CAGR of 5.68% during forecast period 2016-2021. High growth of the market in this region is due to rising healthcare expenditure, increasing cancer patient population, growing involvement of universities & research institutes, and rising focus of foreign pharmaceutical companies on Asian market.

The key players in global Bladder Cancer Therapeutics market include, Sanofi S.A. (France), Novartis AG (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), AstraZeneca plc (U.K.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and Celgene Corporation (U.S.). Browse through the full report at “http://www.marketdataforecast.com/market-reports/global-bladder-cancer-therapeutics-market-1149/” and all reports under Pharmaceuticals category at “http://www.marketdataforecast.com/research-reports/healthcare/pharmaceuticals-1/”